Ofev (Nintedanib): First Tyrosine Kinase Inhibitor Approved for the Treatment of Patients with Idiopathic Pulmonary Fibrosis

Loretta Fala. Am Health Drug Benefits. 2015 Mar.

. 2015 Mar;8(Spec Feature):101-4.

No abstract available

References

1. Coalition for Pulmonary Fibrosis. Facts about idiopathic pulmonary fibrosis. Updated March 10, 2015. www.coalitionforpf.org/facts-about-idiopathic-pulmonary-fibrosis/. Accessed March 13, 2015.
1. Raghu G, Collard HR, Egan JJ, et al; for the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183:788–824. - PMC - PubMed
1. Blackwell TS, Tager AM, Anstrom KJ, et al; for the NHLBI Workshop participants. Strategic planning for idiopathic pulmonary fibrosis research: NHLBI Workshop executive summary—November 27–28, 2012. www.nhlbi.nih.gov/research/reports/strategic-planning-idiopathic-pulmona.... Accessed February 12, 2015.
1. Mayo Clinic staff. Diseases and conditions: pulmonary fibrosis. March 18, 2014. www.mayoclinic.org/diseases-conditions/pulmonary-fibrosis/basics/definit.... Accessed February 15, 2015.
1. National Heart, Lung, and Blood Institute. What causes idiopathic pulmonary fibrosis? September 20, 2011. www.nhlbi.nih.gov/health/health-topics/topics/ipf/causes#. Accessed February 12, 2015.